THE DEAL, AT A GLANCE
From the announcementSouffl Therapeutics
01Who is involvedBacked by Juvia Group, TCG Crossover Management, BB Biotech, Fidelity Management & Research CompanyFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedSouffl Therapeutics raised Series B, announced 2026-10-13From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersSoufflé Therapeutics' oversubscribed $135 Million Series B and Bayer collaboration support advancement of lead clinical programs and a heart-targeted siRNA therapy.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Souffl Therapeutics · Financing Record
Explore source-linked visual explanations for Souffl Therapeutics. Unsupported claims are withheld while source review continues.
Record 13989 · Recorded date: 2026-10-13
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →